Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases.

ABSTRACT:

Background

Fondaparinux sodium, a synthetic pentose sugar, selectively inhibits factor Xa and is mainly used to prevent venous thromboembolism during major lower extremity orthopedic surgeries. It is also utilized for treating unstable angina pectoris and non-ST-segment-elevation myocardial infarction (NSTEMI). Given its extensive clinical application, comprehensive evaluation of its safety profile in clinical practice is essential.

Methods

This pharmacovigilance investigation systematically evaluated the post-marketing safety profile of fondaparinux sodium by leveraging real-world data from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q3 2024), where fondaparinux sodium was the primary suspected drug. To further validate the robustness and generalizab

SUBMITTER: Jin W 

PROVIDER: S-EPMC12916646 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature